GlassScriptPhysician profile
Vineesha Arelli
NPI 1255598363
$34,166.53
in general payments reported to CMS, 2019-2025
27 companies · $5,486 in 2025
The $5,486 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,654 · 2020: $745 · 2021: $467 · 2022: $904 · 2023: $4,046 · 2024: $21K · 2025: $5,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $2,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,750.00 |
| Food and Beverage | $2,646.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29,621.72 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Boston Scientific Corporation | $992.84 | 2019 | |
| Glaxosmithkline, LLC. | $632.65 | 2019-2024 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.77 | 2019-2024 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Insmed, INC. | $401.06 | 2020-2023 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $388.48 | 2021-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $271.82 | 2021-2023 | Glassia |
| Genzyme Corporation | $260.49 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $174.11 | 2022-2024 | Uptravi, Opsumit |
| Grifols USA, LLC | $162.22 | 2019-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $135.67 | 2021-2024 | Yupelri |
| Genentech USA, INC. | $109.11 | 2019-2022 | |
| Harmony Biosciences LLC | $107.94 | 2023 | Wakix |
| Sunovion Pharmaceuticals INC. | $84.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $51.79 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $51.58 | 2023-2024 | Smartvest |
| Jazz Pharmaceuticals INC. | $39.87 | 2021 | |
| Nuwellis, INC. | $39.61 | 2020 | |
| Baxter Healthcare | $35.92 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| La Jolla Pharmaceutical Company | $23.39 | 2024 | Giapreza |
| Pulmonx Corporation | $22.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.86 | 2023 | Quviviq |
| Advanced Respiratory, INC | $20.84 | 2020 | |
| Phadia US INC. | $19.20 | 2022 | |
| Vapotherm INC | $18.66 | 2019 | |
| Amgen INC. | $17.92 | 2024 | Tezspire |
| Philips North America LLC | $16.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineesha Arelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.